Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laureate Pharma has signed a manufacturing and development agreement with AVEO Pharmaceutical for the production of AVEO Pharma’s monoclonal antibody AV-203.
Subscribe to our email newsletter
AV-203 is an ErbB3 (HER3)-targeted antibody, which belongs to a family of four proteins that also includes the epidermal growth factor receptor (EGFR) and the HER2 receptor.
Laureate’s services will include process development, protein production, purification and aseptic filling of AP-203 for AVEO.
The project is presently underway and Laureate expects to supply AVEO with clinical product in the second quarter of 2011.
Laureate Pharma Business Development vice president Steve Johnson said that AVEO has a very impressive pipeline of monoclonal antibody-based products for treatment of cancer and they are pleased to work with them on this exciting antibody product.
"We look forward to a productive and successful relationship with AVEO to provide clinical supply of their monoclonal antibodies," Johnson said.